Introduction
Acute lymphoblastic leukaemia (ALL) is the most common malignancy in children, the group in which acute myelocytic leukaemia (AML) comprises only about 10-15% of leukaemia diagnoses. An infectious aetiology has strongly been suspected. The age distribution of patients in Nordic countries in [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] showed peak incidences of leukaemia at 2 and 3 years of age. 1 The peak of human herpesvirus-6 (HHV-6) infection is half a year earlier, and thus, could well contribute to the development of leukaemia. 2, 3 HHV-6 was identified in 1988 as the cause of exanthema subitum, 4, 5 which is characterised by a high fever during the presence of HHV-6 in CD4
+ T lymphocytes. 6 Other clinical manifestations, such as convulsions, encephalitis, and pulmonary and liver involvement, are seen in association with HHV-6 infection as well. However, more than half of primary infections present no apparent clinical signs. 7 Seroepidemiological studies show, that 80% of the infants at 13 months have antibodies against HHV-6. By 2 years of age the seroprevalence has reached its maximum of about 90%. 8 Reactivations, similar to those seen in other herpesvirus infections, may appear. 9 The virus has been detected in tissue biopsies from lymphoproliferative disorders, such as S100-positive T cell chronic lymphoproliferative disease and Rosai-Dorfman disease. 5 A major issue concerning HHV-6 is the possibility of longterm infection. Salivary gland tissue is the site of virus replication and persistence. 10 Morphologically, HHV-6 is a typical herpesvirus, genetically closely related to human herpesvirus- 7 and human cytomegalovirus. 11 Two major subgroups, A and B, have been identified, 12 with the latter being responsible for most primary infections. 13 HHV-6 is predominantly T lymphotropic, although it can infect a variety of other cell types. In cultures of human haematopoietic cells and cell lines, HHV-6 behaves as a cytopathic virus. After 3-7 days, clear cytomorphological changes are seen: cells enlarge, lose their blastic shape, and become rounded and ballooning refractile cells. 14 Recently, we have observed HHV-6 infection in serum specimens of patients with various acute diseases, and in particular, with newly diagnosed leukaemia. 15, 16 Here, we report a study of HHV-6-specific IgM antibodies in 40 children at the onset of leukaemia, at the time of their diagnosis and prior to therapy.
Materials and methods

Patients
Forty children with leukaemia, 33 with ALL and seven with AML, diagnosed and treated at the Hospital for Children and Adolescents, University of Helsinki, were studied serologically for viral infections at the time of their diagnosis. The age of the children ranged from 7 months to 16 years, with 13 being boys and 27 girls (Figure 1) .
For a reference group, 39 children with various neurological symptoms of suspected viral origin were selected because healthy children cannot be studied for ethical reasons. The subjects were exclusively from the southern part of Finland, from the district of the Helsinki University Central Hospital, and were matched for age (±4 months in children less than 24 months, and ±10 months in older children), sex, and season (winter, spring, summer, autumn).
Methods
Anti-IgG and IgM antibodies against HHV-6 were measured from a panel of 40 serum specimens from patients with leu-
Figure 1
Age distribution of the reference subjects and patients with leukaemia at the time of diagnosis. kaemia and of 39 reference sera from patients with various neurological diseases with suspected viral origin using a commercial enzyme immunoassay (EIA) (PanBio, Brisbane, Australia). The results obtained with both HHV-6-specific IgG and IgM tests were expressed in PanBio units (PBU). The PBU is calculated from the ratio of the sample absorbance to the cut-off absorbance and multiplied by 10 (absorbance of sample/mean absorbance of cut-off × 10).
For the measurement of the HHV-6-specific IgG antibody avidity, an in-house modification of the above commercial kit was used. In the assay the absorbances obtained with incubating different dilutions of serum specimens in Tris-buffered saline in HHV-6-coated wells were compared to the values obtained with dilutions with similar serum incubations followed by three washes with 6 M urea. The optimal four dilutions used to measure the IgG avidity were extrapolated from the initial amount of specific IgG. Serum specimens with a high IgG level were diluted more than the serum specimens with a low IgG level. This means that the avidity curves could all be measured around a similar cut-off range. Thus for each serum specimen, two dilution curves were obtained, one for the serum HHV-6 antibody washed with urea, and the other without urea (urea + and urea − ). The corresponding end-point titres were determined, and their ratios were calculated and expressed as percentages: [titre (urea
Values Ͻ20% indicated acute infection (low avidity), 20-30% borderline avidity, and Ͼ30% old immunity (high avidity). The avidity test was performed from all samples with IgG PBU levels high enough for avidity testing, with 32 patients and 33 reference subjects tested.
Antibodies to HSV-1, HSV-2, VZV, RSV (commercial antigens, Virion, Wü rzburg, Germany), adeno, influenza A and B, rota, coxsackie B5, non-typed entero and parainfluenza 1 viruses, and Mycoplasma pneumoniae (antigens grown and purified as described) were measured from serum by using EIA tests as described elsewhere. 17 
Statistical methods
Fisher's exact two-tailed t-test was used to study statistical differences between groups.
Results
Thirty-nine of 40 (97.5%) children with leukaemia had IgG antibodies against HHV-6, compared with 36 of 39 (92.3%) reference subjects (Figure 1) . The seronegative child with leukaemia seroconverted during the first weeks of therapy, and within 3 weeks of the diagnosis with leukaemia. The IgG level was, however, too low for the measurement of the IgG avidity. Specific IgM antibodies were present in 16 (40%) patients with leukaemia, compared with three (7.7%) in the reference group (P = 0.005). The anti-HHV-6 IgM antibody positivity concentrated in children with leukaemia aged 12-13 years, whereas in reference children the positivity appeared in children under 6 years of age (Figure 2) . We observed no difference in antibody pattern between patients with ALL and those with AML.
The avidity of IgG antibodies was high in all children with leukaemia, indicating a preceding infection (Figure 3 ). In the reference group, one child with low IgG avidity was observed indicating an acute infection (Figure 4 ). This 4-year-old boy was also IgM positive to HHV-6. Three reference subjects had a borderline avidity (20-30%), but they all were IgM negative.
Leukemia
Figure 2
IgM antibodies to HHV-6 in children with leukaemia and reference children. At the follow-up, the IgG antibody level to HHV-6 was stable or increased in 10 out of 25 (40%) patients with leukaemia, despite the induction and maintenance therapy. At the same time the levels of IgM were decreased.
When the antibody prevalences were compared to the altogether 12 other microbes, no significant differences were observed between the children with leukaemia and the control group.
Discussion
Children with leukaemia had a significantly higher prevalence of IgM antibodies against HHV-6 than their matched controls. Especially older children with acute leukaemia showed IgM positivity but still had a high avidity of IgG, indicating an old infection. The finding suggests that the children had a recurrent infection or an inappropriate response to the primary HHV-6 infection. In contrast, three sera from the 39 reference subjects were IgM positive, and one of them had specific IgG antibodies with low avidity indicating an acute infection. These children were being studied for suspected neurological diseases of viral origin. This group was selected due to ethical difficulties in drawing blood samples from healthy children, but was representative since HHV-6 is known to be neurotropic. 2, 18, 19 Virus-specific IgM antibodies usually appear during the second week of HHV-6 infection and persist for a period of 2-3 months, whereas IgG antibodies persist for longer or for life. 20, 21 We observed one low avidity antibody value in a reference child but in none of the children with leukaemia, who all had a high IgG avidity. The dynamics of IgG avidity in HHV-6 infections are poorly known. In regard to HHV-6 only a few studies are available and, using EIA, no avidity tests have been reported. We evaluated the IgG avidity using a commercial kit complemented with an in-house modification of urea treatment. Based on the automated statistical program, the avidity dynamics were reliable. High, low and borderline avidity controls were always included in the test. More experience will be needed, however, to confirm the affinity of IgG in the different phases of the HHV-6 infection.
The newest members of the herpesvirus group, HHV-6, HHV-7 and HHV-8, have oncogenic potential and are found in association with several immunosuppressive conditions. 5, 22, 23 Both A and B subgroups of HHV-6 virus have a primary tropism for CD4 + T lymphocytes. There is evidence, that HHV-6 can directly target natural killer cells, thereby suppressing the natural anti-viral immunity of the host. 24 Primary lymphocyte cultures are used for the isolation of both A and B subgroups. In HHV-6 isolates, phenotypic as well as genetic polymorphism has been reported. The isolates cannot thus be categorised into one or two broad subgroups. 25 Since its discovery, HHV-6 has been considered a candidate oncogenic virus. It has frequently been detected in patients with lymphoma. Seroepidemiological studies have suggested it to be either an aetiological or an ALL-associated agent. 26 The results are not, however, consistent in all reports. [27] [28] [29] [30] Some studies have identified antibodies to HHV-6A, which is not known to cause any human disease. 29, 31 A second dilemma lies in the timing of sampling. The serological status is only diagnostic, when studied prior to initiation of chemotherapy. We collected the samples accordingly. At the follow-up, the IgG antibody level to HHV-6 was stable or had increased in nearly half of the patients, despite intensive chemotherapy. The only HHV-6 seronegative child at the time of diagnosis became seropositive a mere 3 weeks later. Unfortunately, avidity of IgG could not be studied because of the low IgG level, probably due to the induction medication for leukaemia.
Our results suggest a role for HHV-6 in children with leukaemia. This is supported by another study, where HHV-6 DNA was found integrated in early pre-B cell ALL. 32, 33 HHV-6 is known to be able to infect myeloid cell lines latently. 34 It may also infect early bone marrow progenitors in much the same way. 35, 36 We have studied the serological status of children with leukaemia for years, but diagnostic findings have been rare. After having repeatedly identified HHV-6-specific nucleic acid in different patients with leukaemia, we concentrated on studying the serological status to HHV-6 at the onset of the malignant process, prior to any therapy, and found an astonishingly high prevalence of virus-specific IgM antibodies.
The difficulties in differentiating infectious conditions from the malignancy are obvious. [37] [38] [39] Proper studies at the onset of symptoms are extremely important for all patients suspected of having a malignant process. One should be aware of its possible presence as an associated or a putative causative agent in leukaemia. Many factors underline the need to develop new approaches for the study of malignant processes. Promising therapies of the disease are underway, and vaccine development is being evaluated for prevention. Moreover, as the aetiology of childhood leukaemias and lymphomas is largely unknown, our report shows that the HHV-6 infection is a good candidate.
